Introduction
============

Atherosclerotic renal artery stenosis (ARAS) is the most common cause of renal artery stenosis (RAS) and is associated with severe comorbidities such as resistant hypertension, ischemic nephropathy, and end-stage renal disease \[[@b1-krcp-38-336],[@b2-krcp-38-336]\]. Common therapeutic strategies for RAS include medical therapy, angioplasty with or without stenting, and bypass surgery. Percutaneous transluminal angioplasty (PTA) is a highly effective modality for correction of RAS. However, two recent randomized controlled trials (RCT) of PTA for ARAS failed to demonstrate any advantages compared with conventional medical therapy regarding renal protection or prevention of cardiovascular events \[[@b3-krcp-38-336]--[@b6-krcp-38-336]\]. Nevertheless, ARAS frequently progresses despite adequate medical management and results in irreversible renal atrophy. Thus, timely corrections of RAS through PTA with stent insertion (PTA/S) may have a beneficial effect on long-term renal outcomes in selected patients.

Current guidelines for ARAS recommend PTA as a reasonable option for patients with haemodynamically significant RAS with clinical manifestations such as resistant hypertension, unexplained pulmonary edema, or progressive chronic kidney disease \[[@b7-krcp-38-336],[@b8-krcp-38-336]\]. However, patient selection for renal revascularization is sometimes challenging, because limited comparative data are available on the specific phenotype of patients who would benefit from the procedure \[[@b9-krcp-38-336]--[@b11-krcp-38-336]\]. In this study, we investigated the effects of renal revascularization in terms of kidney function and blood pressure (BP) control in patients who received PTA/S for ARAS, classifying subjects into low-risk and high-risk groups. High-risk was defined by clinical presentation including a history of pulmonary edema, refractory hypertension, or rapid deterioration of kidney function accompanied by RAS.

Methods
=======

Study population
----------------

We retrospectively identified 62 subjects with RAS who had undergone PTA/S at a 2,000-bed tertiary hospital between January 2000 and October 2017. We excluded subjects with RAS related to kidney transplantation, fibromuscular dysplasia, or Takayasu's disease; subjects who had a history of previous PTA/S; or those who were lost to follow-up within two weeks after the procedures. Ultimately, 47 subjects were included in this study. The study protocol was reviewed and approved by the Institutional Review Board (IRB) of Samsung Medical Center (2017-11-164). The obtain written informed consent from the participants for this retrospective study was waived by IRB.

Data and definitions
--------------------

The following patient data were collected at the time of PTA/S: age, sex, smoking status, body mass index (BMI), comorbidities (diabetes mellitus, coronary artery disease, peripheral artery disease, stroke), systolic BP (SBP), diastolic BP (DBP), serum albumin, total cholesterol, serum creatinine, spot urine protein-to-creatinine ratio (uPCR), targeted kidney size, contralateral kidney size, stenosis severity of the targeted kidney artery, and medication history including antihypertensive medication. Data on kidney size and stenosis severity of the renal artery were collected through a review of sonographic and angiographic records, respectively. Follow-up data for serum creatinine, SBP, DBP, and BP medical score (BPMS) were collected at one month (± 2 weeks) and at 4 months (± 1 month) after PTA/S.

The estimated glomerular filtration rate (eGFR) was calculated using the Chronic Kidney Disease Epidemiology Collaboration 2009 creatinine equation \[[@b12-krcp-38-336]\]. Post-PTA acute kidney injury is defined as impairment of renal function, measured as either a 25% increase in serum creatinine from baseline or a 0.5 mg/dL increase in absolute serum creatinine value, within 48 to 72 hours of the intervention. We utilized the BPMS scoring system to estimate the antihypertensive agent potency, defined as "BPMS \[[@b13-krcp-38-336]\]---sum of the score of each antihypertensive agent," and by setting the equivalent dose for each ingredient that could yield one point \[[@b14-krcp-38-336]--[@b19-krcp-38-336]\]. Alpha-adrenergic blocking agents considered as antihypertensive agents were terazosin and doxazosin \[[@b20-krcp-38-336]\]. Use of diuretics was assigned as a 1 point to BRMS regardless of the ingredient and dose, assuming that the administered dose was appropriate to maintain euvolemic status.

Through a review of the medical records, we classified the study subjects into two groups: low-risk and high-risk group. The high-risk group was defined as patients with a history of pulmonary edema, refractory hypertension, or rapid deterioration of kidney function accompanied by RAS at baseline (the time of procedure). Pulmonary edema was defined if the chest radiographic imaging showed evidence of pulmonary edema requiring treatment with intravenous medications such as furosemide. Rapid decline of kidney function was defined if the serum creatinine level increased over 25% during the six months prior to PTA/S. Refractory hypertension was defined if the SBP was \> 140 mmHg and/or the DBP was \> 90 mmHg despite the use of three or more different classes of antihypertensive agents, including diuretics, in accordance with the European Society of Hypertension/European Society of Cardiology guidelines \[[@b21-krcp-38-336]\], or if the SBP was \> 155 mmHg despite the use of two or more different classes of antihypertensive agents in accordance with the Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL) trial \[[@b4-krcp-38-336]\]. Patients not satisfying any of the three high-risk clinical features described above were classified into the low-risk group.

The primary outcome was improvement of either kidney function or hypertension after PTA/S. Kidney function improvement was defined as recovery of eGFR over 20% compared to baseline at 4 months (± 1 month) after PTA/S. Hypertension improvement was defined as resolution of refractory hypertension, a decrease in BPMS by more than 2 points, or interrupted use of the BP-lowering agent after 4 months (± 1 month) of PTA/S. Subjects who achieved either kidney function improvement or hypertension improvement were classified as responders. All remaining subjects were classified as non-responders.

Statistical analyses
--------------------

Data are presented as median and interquartile range (IQR). Baseline continuous variables were compared using the independent two sample *t* test or the Mann--Whitney rank sum test according to data distribution, while categorical variables were compared using the chi-square test or Fisher's exact test. Differences in serial eGFR, SBP, DBP, and BPMS between the two groups were assessed by a linear mixed model using a specific subgroup and time as an independent variable. All statistical analyses were performed using IBM SPSS ver. 25.0 for Windows (IBM Corp., Armonk, NY, USA). A *P* value \< 0.05 was considered statistically significant.

Results
=======

Baseline demographics and clinical characteristics of the study subjects
------------------------------------------------------------------------

The baseline characteristics of the study population (n = 47) are summarized in [Table 1](#t1-krcp-38-336){ref-type="table"}. Twenty-one subjects (44.7%) satisfied the criteria of the high-risk group. Among these, 2 subjects presented with pulmonary edema, 7 subjects met the criteria for rapid decline of kidney function, 17 subjects met the criteria for refractory hypertension, and 5 subjects met the criteria for both rapid decline of kidney function and refractory hypertension.

The median age was 68 (58--76) years in the low-risk group and 65 (61--75) years in the high-risk group. The baseline eGFR value was 49 (34--64) mL/min/1.73 m^2^ in the low-risk group and 33 (20--47) mL/min/1.73 m^2^ in the high-risk group. The median changes in kidney function during the six months prior to PTA/S were −1.3 (−4.4 to 2.7) and −4.9 (−17.1 to −1.6) in the low-risk and high-risk groups, respectively (*P* = 0.011). As expected, the high-risk group had higher BP (*P* \< 0.001) and a larger proportion of subjects taking three or more anti-hypertensive agents (*P* = 0.015). The median targeted kidney size was 10.0 (9.0--10.2) cm in low-risk group and 9.8 (9.3--10.2) cm in the high-risk group. Bilateral renal artery stent insertion was performed in 2 subjects (7.7%) in the low-risk group and in 6 subjects (28.6%) in the high-risk group.

Kidney function improvement after PTA/S
---------------------------------------

Among the included patients, 4 subjects were lost to follow-up or death within 4 months from baseline. Among the remaining 43 subjects, 2 subjects (8.0%) and 5 subjects (27.8%) showed kidney function improvement after PTA/S in the low- (n = 25) and high-risk (n = 18) groups, respectively (*P* = 0.11). The proportion of subjects with kidney function improvement increased in those presenting with rapid decline of kidney function (3 out of 5, 60%; low-risk group vs. rapid decline, *P* = 0.022) ([Fig. 1A](#f1-krcp-38-336){ref-type="fig"}). The eGFR improved from 28 (10--45) mL/min/1.73 m^2^ to 41 (16--67) mL/min/1.73 m^2^ at 4 months after PTA/S in subjects with rapid decline of kidney function, although the difference was not statistically significant (*P* = 0.084) ([Fig. 2](#f2-krcp-38-336){ref-type="fig"}). However, the eGFR did not improve after PTA/S in the low-risk group (52 \[42--62\] mL/min/1.73 m^2^ at baseline vs. 51 \[42--60\] mL/min/1.73 m^2^ at 4 months, *P* = 0.541). The time-dependent changes of eGFR between the low-risk group and the rapid decline of kidney function group were significant when adjusted for age, sex, baseline eGFR, SBP, and proteinuria (*P* = 0.001).

Hypertension improvement after PTA/S
------------------------------------

Nine (36.0%) and 14 (77.8%) subjects showed a reduction in BP after PTA/S in the low- (n = 25) and high-risk (n = 18) group, respectively (*P* = 0.007). The proportion of subjects with hypertension improvement further increased in the refractory hypertension group (12 out of 15, 80.0%; low-risk group vs. refractory hypertension group, *P* = 0.007) ([Fig. 1B](#f1-krcp-38-336){ref-type="fig"}). In subjects who presented with refractory hypertension, SBP decreased from 157 (150--164) mmHg at baseline to 140 (131--148) mmHg at 4 months after PTA/S (*P* = 0.005). In the low-risk group, there was a slight decrease in SBP (133 \[129--138\] mmHg at baseline compared to 131 \[124--138\] mmHg at 4 months after PTA/S, *P* = 0.561). There was also a decrease in BPMS in the refractory hypertension group from 3.6 (2.1--5.0) at baseline to 2.8 (1.6--3.9) at 4 months (*P* = 0.050). Conversely, the BPMS changed marginally from 2.0 (1.5--2.6) at baseline to 1.7 (1.0--2.5) at 4 months in the low-risk group (*P* = 0.390) ([Fig. 3](#f3-krcp-38-336){ref-type="fig"}). There was a significant difference in the time-dependent change of SBP (*P* = 0.001) between the low-risk group and the refractory hypertension group when adjusted for age, sex, baseline eGFR, SBP, and proteinuria. However, there was no difference in the time-dependent change of DBP (*P* = 0.061) or BPMS (*P* = 0.627) between the low-risk group and the refractory hypertension group when adjusted for age, sex, baseline eGFR, SBP, and proteinuria.

Outcomes of the pulmonary edema group
-------------------------------------

Two subjects presented with pulmonary edema. One subject was stable without recurrent pulmonary edema until one month after PTA/S when she was lost to follow-up, while pulmonary edema did not recur in the other subject until 4 months after PTA/S.

Clinical characteristics of patients with response after PTA/S
--------------------------------------------------------------

Overall, 25 subjects (58.1%) achieved either kidney function improvement or hypertension improvement and were therefore classified as responders. [Table 2](#t2-krcp-38-336){ref-type="table"} shows the characteristics of responders after PTA/S. The demographic findings of age, sex, history of smoking, BMI, and history of medication showed no difference between responders and non-responders. The baseline SBP was higher in responders than in non-responders (*P* = 0.047). The proportion of subjects who presented with refractory hypertension was higher in responders than in non-responders (*P* = 0.006). All patients with rapidly declining kidney function before PTA/S showed a response after the procedure, although the difference was not significant (*P* = 0.064). The baseline eGFR showed no difference between responders and non-responders (39 \[24--58\] vs. 44 \[30--58\], *P* = 0.961). Among patients with baseline eGFR \< 30 mL/min/1.73 m^2^ (n = 11), 7 subjects (63.6%) met the criteria for responders. There was no difference in the presence of baseline proteinuria between responders and non-responders (*P* = 0.679). Among patients with the targeted kidney size of 7.5 to 8.5 cm (n = 5), 3 subjects (60.0%) met the criteria for responders. The level of targeted arterial stenosis was associated with the response after PTA/S (*P* = 0.040). None of the patients with targeted arterial stenosis less than 75% (n = 4) met the response criteria after PTA/S. When patients with less than 75% stenosis were excluded, the responder group showed a larger proportion of high-risk patients than the non-responder group (responders, 15/25 \[60.0%\]; non-responders, 3/14 \[21%\]; *P* = 0.020), and the proportion of subjects who presented with refractory hypertension (responders, 13/25 \[52%\]; non-responders, 2/14 \[14%\]; *P* = 0.020) or rapid decline of kidney function (responders, 5/25 \[20%\]; non-responders, 0/14 \[0%\]; *P* = 0.073) was higher in responders than in non-responders.

Procedure-related complications
-------------------------------

PTA/S-related complications were reported in 5 of the 47 patients (10.6%): cholesterol embolism in one patient, catheter puncture site haematoma in a second patient, and renal artery dissections in the remaining. Among the 47 patients who underwent PTA/S, post-PTA acute kidney injury occurred in 8 subjects (17.0%).

Discussion
==========

The present study demonstrated that patients with ARAS presenting with high-risk clinical manifestations might benefit from revascularization, which is consistent with previous studies \[[@b9-krcp-38-336],[@b22-krcp-38-336]\]. We found that subjects with rapid deterioration of kidney function showed kidney function improvement, and those with refractory hypertension achieved better control of BP, with a decrease in the number of antihypertensive medications after PTA/S, compared to the low-risk group. In addition, this study suggested that, even if baseline eGFR is \< 30 mL/min/1.73 m^2^, PTA/S may be considered as a treatment option in patients with clinically significant ARAS.

Optimal medical treatment without revascularization has been the 'gold standard' for low-risk and stable ARAS, according to a previously reported RCT and meta-analysis \[[@b10-krcp-38-336]\]. Recently, the two largest RCTs evaluating percutaneous renal artery intervention for RAS, the CORAL trial and the Angioplasty and Stenting for Renal Artery Lesions (ASTRAL) trial, demonstrated that revascularization did not offer significant benefits over medical therapy in patients with ARAS and stable chronic kidney disease \[[@b3-krcp-38-336],[@b4-krcp-38-336]\]. These trials share the limitation of excluding subsets of patients with high-risk clinical presentations, such as episodic pulmonary edema, rapid decline of kidney function, and hypertension \[[@b23-krcp-38-336]\].

In the ASTRAL trial \[[@b3-krcp-38-336]\], the primary outcome measure was change in renal function over time. During a median follow-up period of 34 months, the rate of progression of renal impairment differed, being lower in the revascularization group at 0.06 × 10^−3^ L/μmol per year (95% confidence interval, −0.002 to 0.13; *P* = 0.06). There were no between-group differences in the following secondary outcomes: SBP/DBP, rates of renal events, major cardiovascular events, and death. However, the majority of the patients in the ASTRAL trial had only mild-to-moderate RAS, and about 40% of subjects had a stenosis \< 50% and were least likely to benefit from revascularization. Twenty-five percent of subjects had normal renal function and a further 15% almost-normal renal function at baseline. The aim of the CORAL trial \[[@b4-krcp-38-336]\] was to evaluate "hard" clinical endpoints using cardiovascular or renal events. Over a median follow-up period of 43 months, there were no significant differences between the treatment groups in primary outcomes and overall survival. The original study protocol included patients with 60% to 100% RAS on angiography, with an SBP above 155 mmHg, and taking two or more anti-hypertensive medications. However, there have been changes in the original inclusion criteria due to slow enrollment. As a result, 25% to 30% of patients have shown well-controlled BP, 55% of subjects had \< 70% stenosis, and approximately 50% of the cohort presented normal kidney function.

There have been several studies reporting the benefits of revascularization in high-risk patients with ARAS \[[@b8-krcp-38-336],[@b9-krcp-38-336],[@b22-krcp-38-336],[@b24-krcp-38-336]\]. Patients presenting with a combination of rapidly declining kidney function and refractory hypertension may benefit from revascularization \[[@b22-krcp-38-336]\]. Vassallo et al. \[[@b9-krcp-38-336]\] have recently demonstrated that high-risk patients, especially those presenting with rapidly deteriorating renal function and concurrent bilateral ≥ 70% RAS and low levels of proteinuria (\< 1 g/day) at the time of diagnosis, benefited from revascularization. In their study, high-risk patients were defined as those presenting with ≥ 70% unilateral or bilateral angiographic RAS with at least one high-risk clinical manifestation such as flash pulmonary edema, stage 2 hypertension, or rapidly deteriorating renal function. The study used stricter inclusion criteria for uncontrolled or severe hypertension (SBP ≥ 160 mmHg and/or DBP ≥ 100 mmHg) than the present study. In addition, the definition of rapidly declining kidney function differed from that of the present study, as the eGFR slope was defined as less than −3.0 mL/min/1.73 m^2^/year. In our study, 58% of subjects with baseline uPCR \< 1 mg/mg Cr showed an improvement in kidney function or better control of BP. None of the patients with baseline uPCR \> 1 g/g Cr showed any increase in kidney function after PTA/S (data not shown), but this was not statistically significant, which was likely due to the limited number of patients. Proteinuria may imply the presence of comorbid renal parenchymal disease \[[@b25-krcp-38-336],[@b26-krcp-38-336]\]. In this circumstance, the revascularization of RAS may have little impact on the outcome of kidney disease. In addition, none of the patients with a targeted arterial stenosis \< 75% showed any benefit on revascularization in the present study. These results are consistent with the finding that a RAS greater than 70%--80% is necessary to activate intra-renal RAS \[[@b23-krcp-38-336]\], although identification of haemodynamic significance by anatomical stenotic severity is limited \[[@b11-krcp-38-336],[@b27-krcp-38-336]--[@b29-krcp-38-336]\].

There are several limitations to be mentioned. First, as this was a retrospective study, patients were not randomized to revascularization; hence, selection bias and potential hidden confounders may affect the results. However, considering that recruitment to renal stenting trials is very challenging (e.g., the recruitment phase in the ASTRAL study lasted seven years and approximately two patients per year were enrolled) \[[@b3-krcp-38-336]\], our findings based on retrospective data are worthy of attention. Second, this study was a small single-arm registry study without comparison with an optimal medical therapy arm. Thus, the generalizability of our findings remains to be determined. Third, because of the relatively short follow-up period, we did not examine the effects of revascularization on the long-term effects on the kidney or the patient. Instead, immediate changes in BP and kidney function were evaluated in detail.

The present study investigated the clinical efficacy of revascularization in patients with ARAS and suggested beneficial effects of revascularization on hypertension and kidney function in patients who presented with high-risk clinical features. Patients with stenosis \< 75% showed poorer responses to PTA/S, while an advanced chronic kidney disease stage was not a predictor of poor response to PTA/S. Two recent RCTs of PTA for ARAS failed to demonstrate any advantages on renal protection or prevention of cardiovascular events compared with conventional medical therapy. This study implied that the optimal application of PTA/S should be based on individual assessment of the clinical significance of RAS.
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###### 

Baseline characteristics of the study subjects (n = 47)

  Variable                                           Low-risk (n = 26)     High-risk (n = 21)     *P* value
  -------------------------------------------------- --------------------- ---------------------- -----------
  Age (yr)                                           68 (58--76)           66 (61--75)            0.983
  Sex, male                                          20 (76.9)             15 (71.4)              0.668
  Smoking                                            9 (34.6)              11(52.4)               0.221
  Body mass index (kg/m^2^)                          23.4 (21.8--25.6)     24.0 (22.0--25.3)      0.591
  SBP (mmHg)                                         134 (122--141)        152 (143--160)         0.188
  DBP (mmHg)                                         76 (68--80)           77 (69--88)            \< 0.001
  Comorbidity                                                                                     
   Diabetes mellitus                                 11 (42.3)             13 (61.9)              0.181
   CAD                                               16 (61.5)             9 (42.9)               0.202
   PAD                                               3 (11.5)              7 (33.3)               0.086
   Stroke                                            7 (26.9)              4 (19.0)               0.731
  Baseline eGFR (mL/min/1.73 m^2^)                   49 (34--64)           33 (20--47)            0.046
   \< 30 mL/min/1.73 m^2^                            3 (11.5)              10 (47.6)              0.006
  ΔeGFR[a](#tfn3-krcp-38-336){ref-type="table-fn"}   −1.3 (−4.4 to −2.7)   −4.9 (−17.1 to −1.6)   0.011
  Serum albumin (g/dL)                               4.1 (3.8--4.4)        3.8 (3.6--4.2)         0.118
  Total cholesterol (mg/dL)                          149 (127--168)        149 (132--175)         0.352
  uPCR (mg/mgCr)                                     0.21 (0.09--0.52)     0.31 (0.00--0.93)      0.163
  Targeted kidney size (cm)                          10.0 (9.0--10.2)      9.8 (9.3--10.2)        0.703
  Contralateral kidney size (cm)                     10.0 (9.1--10.0)      9.6 (8.5--10.0)        0.411
  Targeted arterial stenosis                                                                      0.108
   \> 95%                                            4 (15.4)              1 (4.8)                
   75--95%                                           18 (69.2)             19 (90.5)              
   \< 75%                                            4 (15.4)              0 (0)                  
  Bilateral stent insertion                          2 (7.7)               6 (28.6)               0.115
  Concomitant medication                                                                          
   ACEi/ARB                                          8 (30.8)              9 (42.9)               0.391
   Diuretics                                         7 (26.9)              15 (71.4)              0.002
   CCB                                               18 (69.2)             14 (66.7)              0.851
   Beta blocker                                      13 (50.0)             18 (85.7)              0.010
   Alpha blocker                                     2 (7.7)               1 (4.8)                1.000
   Other anti-hypertensive drug                      2 (7.7)               1 (4.8)                1.000
  BPMS                                               1.5 (1.0--3.0)        2.5 (1.8--4.5)         0.020

Data are presented as median (interquartile range) or number (%).

ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BPMS, blood pressure medical score; CAD, coronary artery disease; CCB, calcium channel blocker; Cr, creatinine; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; PAD, peripheral artery disease; SBP, systolic blood pressure; uPCR, urine protein-to-creatinine ratio.

Median change in kidney function between baseline eGFR and pre-procedural eGFR.

The pre-procedural eGFR is the result of the last examination within six months prior to the percutaneous transluminal angioplasty with stent insertion.

###### 

Clinical characteristics by response to percutaneous transluminal angioplasty with stent insertion

  Variable                                                                    Responder (n = 25)     Non-responder (n = 18)   *P* value
  --------------------------------------------------------------------------- ---------------------- ------------------------ -----------
  Age (yr)                                                                    66 (59--75)            69 (58--75)              0.803
  Sex, male                                                                   20 (80.0)              12 (66.7)                0.480
  Smoking                                                                     12 (48.0)              6 (33.3)                 0.336
  Body mass index (kg/m^2^)                                                   24.1 (21.8--25.5)      23.2 (21.9--26.3)        0.674
  Concurrent medication                                                                                                       
   ACEi/ARB                                                                   11 (44.0)              5 (27.8)                 0.278
   Diuretics                                                                  12 (48.0)              11 (61.1)                0.553
   CCB                                                                        16 (64.0)              13 (72.2)                0.570
   Beta blocker                                                               17 (68.0)              12 (66.7)                0.927
   Alpha blocker                                                              2 (8.0)                1 (5.6)                  1.000
   Statin                                                                     16 (64.0)              15 (83.3)                0.163
   Aspirin                                                                    19 (76.0)              11 (61.1)                0.294
   Clopidogrel                                                                12 (48.0)              6 (33.3)                 0.336
   Other antiplatelet                                                         1 (4.0)                1 (5.6)                  1.000
   Warfarin                                                                   5 (20.0)               5 (27.8)                 0.717
  SBP (mmHg)                                                                  150 (132--156)         138 (125--145)           0.047
  DBP (mmHg)                                                                  80 (69--89)            74 (68--80)              0.054
  BPMS                                                                        2.3 (1.4--4.0)         1.8 (1.0--3.0)           0.190
  Baseline eGFR (mL/min/1.73 m^2^)                                            39 (24--58)            44 (30--58)              0.961
   \< 30 mL/min/1.73 m^2^                                                     7 (28.0)               4 (22.2)                 0.736
  ΔeGFR[a](#tfn7-krcp-38-336){ref-type="table-fn"}                            −3.9 (−10.7 to −0.7)   −1.3 (−4.2 to −1.7)      0.050
  uPCR (mg/mgCr)                                                              0.20 (0.08--0.42)      0.31 (0.06--0.95)        0.117
  Proteinuria[b](#tfn8-krcp-38-336){ref-type="table-fn"} (g/gCr)                                                              0.679
   \< 1                                                                       20 (87.0)              14 (77.8)                
   ≥ 1                                                                        3 (13.0)               4 (22.2)                 
  Contralateral kidney size[c](#tfn9-krcp-38-336){ref-type="table-fn"} (cm)   10.0 (9.1--10.0)       9.4 (8.9--10.0)          0.379
   7.5--8.5                                                                   3 (17.6)               2 (15.4)                 1.000
  Targeted kidney size (cm)                                                   9.9 (9.3--10.1)        10.0 (8.9--10.2)         0.959
   7.5--8.5                                                                   2 (8.0)                2 (11)                   1.000
  Targeted arterial stenosis[d](#tfn10-krcp-38-336){ref-type="table-fn"}      89 (80--95)            85 (74--95)              0.183
   \> 95%                                                                     3 (12.5)               2 (11.1)                 
   75--95%                                                                    21 (87.5)              12 (66.7)                0.040
   \< 75%                                                                     0 (0)                  4 (22.2)                 
  Bilateral stent insertion                                                   5 (20.0)               3 (16.7)                 1.000
  Low-risk/high-risk                                                          10 (40.0)/15 (60.0)    15 (83.3)/3 (16.7)       0.004
  Refractory hypertension                                                     13 (52.0)              2 (11.1)                 0.006
  Rapid decline of kidney function                                            5 (20.0)               0 (0)                    0.064

Data are presented as median (interquartile range) or number (%).

ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BPMS, blood pressure medical score; CCB, calcium channel blocker; DBP, diastolic blood pressure; SBP, systolic blood pressure; eGFR, estimated glomerular filtration rate; uPCR, urine protein-to-creatinine ratio.

Median change in kidney function between baseline eGFR and pre-procedural eGFR. The pre-procedural eGFR is the result of the last examination within six months prior to the PTA/S.

Data regarding baseline uPCR were not routinely collected. Total number of responders was 23 due to missing data for two subjects.

Data regarding contralateral kidney size were not routinely measured. Total numbers of responders and non-responders were 17 and 13, respectively, due to missing data for 13 subjects.

Data regarding targeted arterial stenosis were not routinely collected. Total number of responders was 24 due to missing data for one subject.

*P* values were calculated using either the Mann--Whitney *U* test or Fisher's exact test.
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